Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27650161 | 0.79 | MAOB (0.49) | NISCHMAOBPDCD1LG2CD274 | |
| SCHEMBL28710992 | 0.78 | SYK (0.50) | — | |
| SCHEMBL2781659 | 0.76 | NISCH (0.74) | NISCHADRA1A | |
| SCHEMBL5797361 | 0.75 | MEN1 (0.56) | CD274 | |
| SCHEMBL29496946 | 0.75 | MEN1 (0.56) | CD274 | |
| SCHEMBL31743071 | 0.74 | NISCH (0.54) | NISCHPDCD1LG2CD274 | |
| SCHEMBL6766750 | 0.74 | ALDH1A1 (0.59) | ADRA2B | |
| SCHEMBL14668861 | 0.74 | ERN1 (0.48) | — | |
| SCHEMBL29141516 | 0.74 | ERN1 (0.51) | — | |
| SCHEMBL23956338 | 0.74 | ERN1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | NISCH 3084/4885MAOB 1301/4885PDCD1LG2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.